Cedars-Sinai signs on to test prostate cancer patients with Decipher Prostate Cancer Classifier under innovative data sharing program between physicians from leading cancer centers
San Diego, October 13, 2015 – GenomeDx Biosciences today announced that Cedars-Sinai has partnered with the company on the Decipher® Genomics Resource Information Database (Decipher GRIDTM), a clinical genomics data sharing program that unites physicians from leading cancer centers with GenomeDx’s full genome profiling platform.
Cedars-Sinai is a world-renowned academic medical center consistently recognized for its commitment to patient care and innovation, treating more than 500 men with prostate cancer every year. By joining GRID, the largest accessible genomic expression database for urologic cancers, clinicians at Cedars-Sinai can utilize real-time genomic data for the patients they treat and ultimately make more personalized treatment decisions. Over time, data collected will be used to study even larger populations of patients to further identify biomarkers that may be predictive of treatment response. Through the program, Cedars-Sinai will also use GenomeDx’s commercially available Decipher Prostate Cancer Classifier to aid with treatment decisions following prostate cancer surgery. GenomeDx is conducting whole genome profiling for patients included in the program and matching those data to prospectively collected clinical outcomes for patients treated at major cancer centers.
“GenomeDx has built a tremendous genomic repository in GRID, and through partnerships with groups like Cedars-Sinai we can marry the power of genomic information with prospective clinical outcomes for patients,” said Doug Dolginow, M.D., CEO of GenomeDx. “The only way to truly accelerate our understanding of the molecular implications of this disease is to make available and evaluate large datasets. The collaborative nature of GRID allows us to do just that.”
Hyung Kim, M.D., Director of Academic Urology and Associate Director of Surgical Research at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, added,
“Decipher GRID will provide us with research-based genomic information that will allow us to make discoveries to better serve our patients.”
The program around Decipher GRID is initially for men with prostate cancer and is expected to expand into other urologic cancers. Patients participating in the program will benefit from initial testing with the Decipher Prostate Cancer Classifier (www.DecipherTest.com). As a part of standard clinical testing, whole genome information will be collected allowing for customized genomic reporting for clinicians and their patients, providing additional research insights that may be important for clinical care. As the program grows, GenomeDx will collaborate on large-scale clinical studies to harness the vast amounts of genomic data stored in the Decipher GRID.
About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient’s whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.
Learn more at www.DecipherGRID.com
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.
Learn more at www.DecipherTest.com and follow Decipher on Twitter.
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx’s Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRIDTM, the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.
Learn more at www.GenomeDx.com and follow us on Twitter, LinkedIn and YouTube.
About Cedars Sinai Medical Center
Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars-Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow’s health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents.
Learn more at: www.cedars-sinai.edu
Media Contact for GenomeDx Biosciences:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com